Neurotoxicity of intrathecal Shiga toxin 2 and protection by intrathecal injection of anti-Shiga toxin 2 antiserum in rabbits

Microbial Pathogenesis

Volumn 25, Issue 3, 1998, Pages 139-146

  Fujii, Jun ^a   Kinoshita, Yoshimasa ^a   Yamada, Yoji ^a   Yutsudo, Takashi ^b   Kita, Toshiro ^a   Takeda, Tae ^c   Yoshida, Shin Ichi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Blood brain barrier; Central nervous system; Cerebrospinal fluid brain barrier; Shiga toxin (Stx) producing E. coli; Stx2 (Shiga toxin 2)

Indexed keywords

SHIGA TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN DISEASE; BRAIN THIRD VENTRICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; LD 50; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALIA; ESCHERICHIA COLI; NEGIBACTERIA; ORYCTOLAGUS CUNICULUS;

EID: 0031726234     PISSN: 08824010     EISSN: None     Source Type: Journal    
DOI: 10.1006/mpat.1998.0220     Document Type: Article

References (23)

1. Hamano S, Nakanishi Y, Nara T, et al. Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan. Acta Paediatr 1993; 82: 454-8.
2. Karmali MA. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 1989; 2: 15-38.
3. Rooney JC, Anderson RM, Hopkins IJ. Clinical and pathological aspects of central nervous system involvement in the haemolytic uraemic syndrome. Aust Paediatr J 1971; 7: 28-33.
4. Upadhyaya K, Barwick K, Fishaut M, Kashgarian M, Siegel NJ. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics 1980; 65: 115-20.
5. Fujii J, Kita T, Yoshida S, et al. Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice. Infect Immun 1994; 62: 3447-53.
6. Linggood MA, Thompson JM. Verotoxin production among porcine strains of Escherichia coli and its association with oedema disease. J Med Microbiol 1987; 24: 359-62.
7. Lindgren SW, Melton AR, O'Brien AD. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect Immun 1993; 61: 3832-42.
8. Strockbine NA, Jackson MP, Sung LM, Holmes RK, O'Brien AD. Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J Bact 1988; 170: 1116-22.
9. Takao T, Tanabe T, Hong YM, et al. Identity of molecular structure of Shiga-like toxin I (VT1) from Escherichia coli O157:H7 with that of Shiga toxin. Microb Pathog 1988; 5: 57-69.
10. Jackson MP, Newland JW, Holmes RK, O'Brien AD. Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb Pathog 1987; 2: 147-53.
11. Lingwood CA, Law H, Richardson S, et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 1987; 262: 8834-9.
12. Waddell T, Head S, Petric M, Cohen A, Lingwood C. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun 1988; 152: 674-9.
13. DeGrandis S, Law H, Brunton J, Gyles C, Lingwood CA. Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem 1989; 264: 12520-5.
14. Fujii J, Kinoshita Y, Kita T, et al. Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect Immun 1996; 64: 5053-60.
15. Mizuguchi M, Tanaka S, Fujii I, et al. Neuronal and vascular pathology produced by verocytotoxin 2 in the rabbit central nervous system. Acta Neuropathol Berl 1996; 91: 254-62.
16. Richardson SE, Rotman TA, Jay V, et al. Experimental verocytotoxemia in rabbits. Infect Immun 1992; 60: 4154-67.
17. Zoja C, Corna D, Farina C, et al. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J Lab Clin Med 1992; 120: 229-38.
18. Wiley RG, Donohue RA, Keusch GT. Axonally transported Shigella cytotoxin is neuronotoxic. J Neuropathol Exp Neurol 1985; 44: 496-506.
19. Armstrong GD, Rowe PC, Goodyer P, et al. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis 1995; 171: 1042-5.
20. Siegler RL. Management of hemolytic-uremic syndrome. J Pediatr 1988; 112: 1014-20.
21. Robson WL, Leung AK, Kaplan BS. Hemolytic-uremic syndrome. Curr Probl Pediatr 1993; 23: 16-33.
22. Wadolkowski EA, Sung LM, Burris JA, Samuel JE, O'Brien AD. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 1990; 58: 3959-65.
23. Yutsudo T, Nakabayashi N, Hirayama T, Takeda Y. Purification and some properties of a Vero toxin from Escherichia coli O157:H7 that is immunologically unrelated to Shiga toxin. Microb Pathog 1987; 3: 21-30.